In a bortezomib-resistant lymphoma cell line, increased TCF4 expression and increased transcription by the TCF-4/β-catenin complex was observed, accompanied by upregulation of their downstream target genes (c-myc and cyclin D1) (8). The gene discussed is TCF4; the disease is lymphoma.